A webinar series, titled “3rd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA,” is slated to hold from October 10th through 26th, starting daily at 1:00 pm EST. This digital event comes with an especial interest for legal professionals and business executives involved in the biopharmaceutical industry as it aims to provide a comprehensive understanding of Hatch-Waxman and BPCIA essentials.
The event’s organizer, the American Conference Institute (ACI), aims to ensure attendees gain vital and up-to-date knowledge pertinent to the evolving landscape of Hatch-Waxman and BPCIA litigation and regulation. This knowledge is all the more crucial for newcomers to the field, including novice attorneys and life sciences industry executives.
The Hatch-Waxman Act, formally known as the Drug Price Competition and Patent Term Restoration Act, facilitates the production of generic drugs by simplifying the FDA approval process while also extending patent exclusivity periods for innovator drugs. On the other hand, the Biologics Price Competition and Innovation Act (BPCIA) governs the approval pathway for biosimilar and interchangeable biological products.
This proficiency series, held over three weeks, is designed to impart a solid foundation for understanding the complex interplay between the two acts. As such, the detailed explanation to newcomers and veterans alike is set to enrich their grasp of this tricky legal space.
For more information on the event or to sign up, visit the official ACI portal.